Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Two new fast-growing oncology companies join the Innovation Gateway at the London Cancer Hub
Two new oncology companies, Kindling Bio and Beckman Coulter, have been secured as tenants at the Innovation Gateway, a leading life sciences incubator at the heart of the London Cancer Hub.
Innovative dual treatment shows promise in tackling deadly cancer
A new study has revealed a promising therapeutic strategy for pancreatic cancer, offering new hope for people living with this disease.
Athena Swan Silver renewal recognises ICR’s continued progress in fostering an inclusive research culture
The Institute of Cancer Research has been granted an Athena Swan Silver Award for a further four years, in recognition of the ICR’s continued progress in embedding gender equality and fostering an inclusive research culture.
ICR Centre for Protein Degradation and NEOsphere Biotechnologies announce research collaboration to discover new molecular glue degrader therapeutics
ICR Centre for Protein Degradation and NEOsphere Biotechnologies announce research collaboration to discover new molecular glue degrader therapeutics.